GlassScriptPhysician profile
Daniel R Cabanero
NPI 1801525472
$2,893.54
in general payments reported to CMS, 2019-2025
27 companies · $1,387 in 2025
The $1,387 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $459 · 2024: $1,048 · 2025: $1,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,663 · Education: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,662.59 |
| Education | $230.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $386.47 | 2024-2025 | Erleada, Carvykti, Rybrevant |
| Teleflex LLC | $277.77 | 2024-2025 | Urolift, Barrigel |
| Astellas Pharma US INC | $207.89 | 2024-2025 | Xtandi |
| Coloplast Corp | $180.23 | 2023 | |
| Blue Earth Diagnostics | $177.13 | 2023-2024 | |
| Myriad Genetic Laboratories, INC. | $160.00 | 2023 | Prolaris |
| Bayer Healthcare Pharmaceuticals INC. | $127.67 | 2025 | |
| Pfizer INC. | $127.65 | 2023-2025 | |
| Accord Healthcare, INC. | $126.97 | 2023-2025 | |
| Antares Pharma, INC. | $110.43 | 2024 | Xyosted |
| Astellas Pharma Global Development | $95.32 | 2025 | Xtandi |
| Progenics Pharmaceuticals, INC. | $93.73 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $89.92 | 2024-2025 | Gemtesa |
| Abbvie INC. | $79.99 | 2024-2025 | |
| Tolmar, INC. | $77.31 | 2024-2025 | Eligard |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $73.18 | 2023-2024 | Axonics, Bulkamid |
| Novartis Pharmaceuticals Corporation | $71.04 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $64.60 | 2025 | Provenge |
| Merck Sharp & Dohme LLC | $63.81 | 2025 | Keytruda, Keytruda Qlex |
| Endo USA, INC. | $54.94 | 2024-2025 | Xiaflex, Aveed |
| Medtronic, INC. | $54.76 | 2025 | Interstim |
| Convatec INC. | $46.18 | 2024 | |
| Urogen Pharma, INC. | $41.73 | 2024 | |
| Laborie Medical Technologies Corp. | $37.37 | 2025 | |
| Telix Pharmaceuticals | $30.52 | 2025 | Illuccix |
| Boston Scientific Corporation | $22.79 | 2025 | Axonics |
| Glaxosmithkline, LLC. | $14.14 | 2025 | Benlysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Cabanero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.